Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antipsychotic medication
|
| gptkbp:approvalYear |
1997
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
N05AH04
|
| gptkbp:brand |
gptkb:Seroquel
gptkb:Seroquel_XR |
| gptkbp:CASNumber |
111974-69-7
|
| gptkbp:contraindication |
hypersensitivity to quetiapine
|
| gptkbp:discoveredBy |
gptkb:AstraZeneca
|
| gptkbp:drugInteraction |
CYP3A4 inhibitors
CYP3A4 inducers central nervous system depressants |
| gptkbp:eliminationHalfLife |
about 6 hours
|
| gptkbp:excretion |
urine
feces |
| gptkbp:form |
extended release tablet
immediate release tablet |
| gptkbp:hasMolecularFormula |
C21H25N3O2S
|
| https://www.w3.org/2000/01/rdf-schema#label |
Quetiapine
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
dopamine D2 receptor antagonist
serotonin 5-HT2A receptor antagonist muscarinic receptor antagonist histamine H1 receptor antagonist alpha-1 adrenergic receptor antagonist |
| gptkbp:metabolism |
gptkb:CYP3A4
liver |
| gptkbp:overdoseSymptoms |
hypotension
tachycardia somnolence |
| gptkbp:patentExpired |
2011 (US)
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:riskFactor |
suicidal thoughts
QT prolongation neuroleptic malignant syndrome tardive dyskinesia |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:orthostatic_hypotension
constipation dizziness weight gain drowsiness dry mouth increased cholesterol extrapyramidal symptoms (rare) increased blood sugar |
| gptkbp:usedFor |
gptkb:generalized_anxiety_disorder
gptkb:major_depressive_disorder bipolar disorder schizophrenia |
| gptkbp:bfsParent |
gptkb:Quetiapine_(off-label)
|
| gptkbp:bfsLayer |
7
|